In a population study by Simonson et al. (2022), pwCF that were on CFTR modulator therapy were observed in lower proportions in the COVID-19 positive group with symptomatic disease compared to patients who were not treated with this therapy (Simonson et al., 2022). Here, CFTR is linked to COVID-19.